Nations within a nation: variations in epidemiological transition across the states of India, 1990—2016 in the Global Burden of Disease Study. Lancet 2017 Dec;390(10111):2437-2460.
India — diabetes capital of the world: now heading towards hypertension. J Assoc Physicians India 2007 May;55:323-324.
India towards diabetes control: key issues. Australas Med J 2013 Oct;6(10):524-531.
National diabetes fact sheet: national estimates and general information on diabetes and prediabetes in the United States. Atlanta (GA): CDC; 2011.
Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 1998 Jul;339(4):229-234.
Is diabetes a coronary risk equivalent? Systematic review and meta-analysis. Diabet Med 2009 Feb;26(2):142-148.
Diabetes and prior coronary heart disease are not necessarily risk equivalent for future coronary heart disease events. J Gen Intern Med 2016 Apr;31(4):387-393.
Trends in hypertension prevalence, awareness, treatment and control in older Mexican Americans, 1993-2005. Ann Epidemiol 2011 Jan;21(1):15-25.
Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998 Sep;352(9131):837-853.
Novel diabetes drugs and the cardiovascular specialist. J Am Coll Cardiol 2017 May;69(21):2646-2656.
Impact of glucose-lowering drugs on cardiovascular disease in type 2 diabetes. Euro Heart J 2015 Sep;36(34):2288-2296.
Pharmacokinetic and pharmacodynamic profile of empagliflozin, a sodium glucose cotransporter 2 inhibitor. Clin Pharmacokinet 2014 Mar;53(3):213-225.
Empagliflozin improves blood pressure in patients with type 2 diabetes (T2DM) and hypertension. Diabetologia 2013 Nov;56(Suppl 1):S377.
Canagliflozin provides durable glycemic improvements and body weight reduction over 104 weeks versus glimepiride in patients with type 2 diabetes on metformin: a randomized, double-blind, phase 3 study. Diabetes Care 2015 Mar;38(3):355-364.
Pharmacodynamic effects of canagliflozin, a sodium glucose co-transporter 2 inhibitor, from a randomized study in patients with type 2 diabetes. PLoS One 2014 Aug;9(8):e105638.
Dapagliflozin maintains glycaemic control while reducing weight and body fat mass over 2 years in patients with type 2 diabetes mellitus inadequately controlled on metformin. Diabetes Obes Metab 2014 Feb;16(2):159-169.
Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 2015 Nov;373(22):2117-2128.
Cardiovascular outcomes and safety of empagliflozin in patients with type 2 diabetes mellitus and peripheral artery disease a subanalysis of EMPA-REG OUTCOME. Circulation 2017 Nov;136:032031.
Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med 2017 Aug;377(7):644-657.
Canagliflozin for primary and secondary prevention of cardiovascular events results from the CANVAS Program (Canagliflozin Cardiovascular Assessment Study). Circulation 2017 Nov;137:032038.
Cardiovascular effects of dapagliflozin in patients with type 2 diabetes and different risk categories: a meta-analysis. Cardiovasc Diabetol 2016 Feb;15:37.
Effects of sodium-glucose cotransporter-2 inhibitors on cardiovascular events, death, and major safety outcomes in adults with type 2 diabetes: a systematic review and meta-analysis. Lancet Diabetes Endocrinol 2016 May;4(5):411-419.
Sodium glucose cotransporter 2 inhibitors in the treatment of diabetes mellitus cardiovascular and kidney effects, potential mechanisms, and clinical applications. Circulation 2016 Sep;134(10):752-772.
Pharmacologic approaches to glycemic treatment. Diabetes Care 2017 Jan;40(Suppl 1):S64-S74.
